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anterior descending artery in 60 rats. 2 weeks later, animals were
randomized to receive of 5106 MSCs labeled with PKH26 in phos-
phate buffer solution (PBS) (30 rats) or PBS (30 rats) alone injection
into the infarction zone in the anterior ventricular free wall. 2, 6 and
12 weeks after MSCs or PBS injection, VFT was measured on infarct
zone, infarct marginal zone and non-infarct zone (each period for 10
rats in MSCs group and 10 rats in PBS group). Labeled MSCs were
observed in 5mm cryostat sections from each harvested heart.
RESULTS In the MSCs group, there were signiﬁcant improvements in
VFT only on the non-infarct zone compared with the PBS group in
short-term period (infarct zone: 3.10.9mA vs 3.70.9mA P＞0.05
infarct marginal zone: 3.00.9mA vs 3.61.6mA P＞0.05 non-infarct
zone: 4.91.2mA vs 2.30.7mA P＜0.05). However, in medium-term
(infarct zone: 4.21.6mA vs 4.01.6mA, infarct marginal zone:
2.91.9mA vs 2.50.8mA, non-infarct zone: 5.12.6mA vs 3.41.0mA.
P＞0.05) and long-term period (infarct zone: 3.91.3mA vs 4.51.7mA,
infarct marginal zone: 5.22.4mA vs 3.51.2mA, non-infarct zone:
5.02.0mA vs 3.51.4mA. P＞0.05), VFT was no improved in the MSCs
group. Labeled MSCs were identiﬁed on infarct zone and infarct
marginal zone, and expressed a-sarcomeric actin and rarely Con-
nexin-43.
CONCLUSIONS The MSCs transplantation only improves the VFT in
non-infarct zone in the short-term period. Meanwhile, the MSCs
transplantation cannot improve the VFT in medium-term and long-
term period. The MSCs differentiated into cardiomyocytes on infarct
zone and infarct marginal zone, but expressed rarely Connexin-43.
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OBJECTIVES The purpose of this study was to clarify whether the
transplantation of adipose derived stem cells (ADSCs) increases or
decreases the incidence of ventricular tachyarrhythmias (VT) in a rat
model of myocardial infarction (MI).
METHODS MI was induced experimentally by permanent occlusion of
the left anterior descending artery of Lewis rats. ADSCs were har-
vested from GFP-transgenic rats, and were cultured until passage
four. ADSCs (10106) resuspended in 100mL saline or pro-survival
cocktail (PSC), which enhances cardiac graft survival, were injected
directly into syngeneic rat hearts 1week after MI.
RESULTS The recipients of ADSCs suspended in PSC had a larger graft
area compared with those receiving ASDCs suspended in saline at 1
week post-transplantation (number of graft cells/section: 149.811.6
vs. 23.44.4, p<0.05, n¼5/group). Thereafter, all ADSC recipients
were transplanted with ASDCs in PSC. ADSCs were transplanted into
infarcted hearts, and the mechanical and electrophysiological func-
tions were assessed. Echocardiography revealed that ADSC recipients
had improved contractile function compared with those receiving PSC
vehicle (fractional shortening: 21.20.8 vs. 15.21.3, p<0.05, n12/
group). Four weeks post-transplantation, VT was induced via in vivo
programmed electrical stimulation. The recipients of ADSCs showed a
signiﬁcantly lower incidence of induced VT compared with the control
(33.2% vs. 84.6%, p<0.05, n12/group).
CONCLUSIONS ADSCs transplantation decreased conduction velocity
and its dispersion in the peri-infarct area. These results suggest that
ADSCs transplantation could improve cardiac mechanical and elec-
trophysiological functions in rat after MI.
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OBJECTIVES Diabetes mellitus (DM) is one of the most prevalent and
serious metabolic diseases. Various complications of type 2 diabetes
mellitus (T2DM) are more harmful than T2DM itself, such as two
to four times the risk of cardiovascular diseases. CD226 is aco-stimulatory adhesion molecule expressed on immune cells.
Signaling cascades involving stimulation of CD226 lead to various
biological responses, including immune cell activation and target cell
lysis. Thus, CD226 appears to be an integral molecule in immune
response in cancer, allergic inﬂammatory disorders and autoimmune
diseases. Recently, emerging evidence supports the role of CD226 in
type 1 DM (T1DM), suggesting that it may be involved in the regulation
of glucose homeostasis. The aim of the present study was to investi-
gate the effect of CD226 on type 2 DM (T2DM).
METHODS C57BL/6 wild type (WT) and CD226 gene-knockout (KO)
mice were fed with high fat diet (HFD) for 14 weeks. We evaluated the
possible function of CD226 in glucose metabolism in this HFD-induced
diabetic mouse model. Human umbilical vein endothelial cells
(HUVECs) were isolated and cultured in endothelial cell growth me-
dium-2 (normal glucose) or added glucose to concentration at 30 mM
(high glucose), stimulated with/without palmitate, TNF-a or CoCl2.
The change of CD226 expression was examined. In addition, the role
of CD226 in glucose uptake in endothelial cells was measured by using
D-glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) mino]-2-
deoxy-d-glucose(2-NBDG). The soluble CD226 level in sera from pa-
tients with T2DM as well as normal subjects was detected by ELISA.
RESULTS The intraperitoneal glucose tolerance test demonstrated
that the CD226 KO mice exhibited improved glucose tolerance.
Consistent with this change, high fat feeding evoked markedly
compensatory increased islet size in WT mice, but not in CD226 KO
mice. RT-PCR results indicated that CD226 was expressed in glucose
metabolic tissues and cardiovascular system. Immunohistochemistry
staining results further suggested that CD226 was located on endo-
thelial system. In addition, the expression of CD226 was signiﬁcantly
increased in HUVECs cultured in hyperglycemic conditions in the
presence of TNF-a compared with that in normal glucose condition.
More importantly, knockdown CD226 with human ShRNA lentivirus
signiﬁcantly increased 2-NBDG uptake by 10.63.1% in the presence of
TNF-a, and the mean ﬂuorescence intensity (MFI) was 112.923.1 (P<
0.05 vs TNF-a group). TNF-a alone decreased the cell glucose uptake
compared with the control group by 8.23.2%, and the MFI was
45.53.9. Furthermore, soluble CD226 in sera from patients with
T2DM following oral glucose tolerance test at 1 h, 2 h and 3 h were
higher compared with fasting status.
CONCLUSIONS We conclude that low-grade inﬂammation increased
CD226 expression under high glucose state, resulting in decreased
glucose uptake in endothelial cells, suggesting that CD226 may play a
critical role in glucose metabolism, especially in T2DM.
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OBJECTIVES To identify the speciﬁc metabolic changes by perform-
ing the metabolomics analyses on the serum of acute ST-segment
elevation myocardial infarction(ASTEMI) patients.
METHODS Ultraperformance liquid chromatography/electrospray
ionization quadruple time-of-ﬂight mass spectrometry (UPLC-Q-TOF-
MS/MS) and multivariate statistical analysis combined with statistical
analysis unit were used to analyze the serum of ASTEMI patients
group (n¼15) in comparison with the healthy control group(n¼10).
Further chemiluminescence detection of dehydroepiandrosterone
sulfate(DHEAS) was carried out to verify some of the metabolomics
ﬁndings from the ASTEMI patients.
RESULTS UPLC-Q-TOF-MS/MS revealed that ASTEMI patients and
healthy control individuals exhibited distinct metabolomics proﬁles.
Principal component analysis (PCA) and partial least squares
discriminant analysis(PLS-DA) demonstrated that ASTEMI patients
and healthy control groups were resided in different regions. By using
multivariate statistical analysis and statistical analysis, at least nine
metabolites were found to markedly differ in the serum of ASTEMI
group from those in the healthy individuals. Some differences
revealed by the metabolomics study, such as the signiﬁcant reduction
of DHEAS in the serum of ASTEMI patients, were further conﬁrmed by
independent chemiluminescence measurements (P¼0.000).
CONCLUSIONS The unbiased metabolomics analyses reveal that
there are signiﬁcant differences ASTEMI patients and healthy controls
on serum metabolite levels. At least nine metabolites in the serum are
found to be associated with ASTEMI. These ﬁndings may provide new
insights regarding the metabolism alterations in ASTEMI patients.
